Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
August 2, 2019
Bionano Genomics to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 8
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ...
August 2, 2019
Athenex Provides an Update Regarding the Vasopressin Case
BUFFALO, N.Y., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
August 2, 2019
Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th
VANCOUVER, Aug. 2, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve ...
August 2, 2019
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and ...
August 1, 2019
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
DURECT Corporation (DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update. Total revenues were $4.0 million ...
August 1, 2019
Chiasma to Report Second Quarter Financial Results on August 8, 2019
WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and ...
August 1, 2019
Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that the Cystic Fibrosis ...
August 1, 2019
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and ...
August 1, 2019
iCAD Reports Second Quarter 2019 Financial Results
NASHUA, N.H., Aug. 01, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported ...
August 1, 2019
Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will ...
August 1, 2019
Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO) today announced its operating and financial results for the second quarter ...
August 1, 2019
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous ...
August 1, 2019
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors
SHANGHAI, China and SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on ...
August 1, 2019
Pfenex and Arcellx Announce a Development, Evaluation and License Agreement
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Arcellx, Inc. today announced a Development, Evaluation and License agreement under ...
August 1, 2019
Albireo to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast
BOSTON, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
August 1, 2019
Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
WARREN, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has ...
August 1, 2019
CorMedix Inc. to Report Second Quarter 2019 Financial Results and Provide a Corporate Update on August 13
BERKELEY HEIGHTS, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
August 1, 2019
Acer Therapeutics to Present at the 2019 Webush PacGrow Healthcare Conference
NEWTON, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
August 1, 2019
Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference
MARINA DEL REY, Calif., Aug. 1, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for ...
August 1, 2019
Zealand Pharma hosts conference call on August 15 at 4 pm CET (10 am EST) to present first half results for 2019
Copenhagen, August 1, 2019 – Zealand Pharma A/S (“Zealand”) (ZEAL) (CVR no. 20 04 50 78) announces that it will host a conference call on ...
Page 2 of 158